Content about Birth control

December 26, 2013

Actavis last year gained approval for its Next Choice, a generic version of Teva Women’s Health’s Plan B One-Step, that now sits on top in emergency contraceptive sales.

PARSIPPANY, N.J. — Actavis last year gained approval for its Next Choice, a generic version of Teva Women’s Health’s Plan B One-Step, that now sits on top in emergency contraceptive sales. For the 52 weeks ended Oct. 6, Next Choice generated $115.2 million fueled by 20.2% growth. Plan B One-Step is ranked No. 2 with $96.4 million in sales, down 10.7%. Earlier this year, the FDA increased access to emergency contraceptives by no longer requiring that they be placed behind the pharmacy counter.

November 26, 2013

The Food and Drug Administration is reviewing emergency contraceptives like Plan B One-Step on whether they are less effective in women weighing more than 165 lbs, according to a report published Monday by Reuters.

NEW YORK — The Food and Drug Administration is reviewing emergency contraceptives like Plan B One-Step on whether they are less effective in women weighing more than 165 lbs., according to a report published Monday by Reuters

November 6, 2013

Healthy Mama on Monday announced the launch of their full line of pregnancy-friendly OTC products in buybuy Baby stores.

NEW YORK — Healthy Mama on Monday announced the launch of their full line of pregnancy-friendly OTC products in Buybuy Baby stores. 

Healthy Mama is a complete brand developed to provide pregnant and nursing women with the safest solutions to such common ailments as aches and pains, lack of energy, nausea, indigestion, constipation and sleeplessness.

May 6, 2013

Swiss Precision Diagnostics unveiled the new Clearblue Advanced Pregnancy Test with Weeks Estimator at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists here.

NEW ORLEANS — Swiss Precision Diagnostics on Monday unveiled the new Clearblue Advanced Pregnancy Test with Weeks Estimator at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists here. The latest home pregnancy test kit not only tells a woman if she is pregnant but also estimates the number of weeks since ovulation. 

May 1, 2013

Bayer HealthCare will buy birth-control product maker Conceptus for $1.1 billion, the companies said.

LEVERKUSEN, Germany — Bayer HealthCare will buy birth-control product maker Conceptus for $1.1 billion, the companies said.

Bayer said its $31-per-share purchase of the Mountain View, Calif.-based company would allow it to expand its selection of contraception products. Conceptus makes Essure, a non-surgical permanent birth-control method, and Bayer said it would allow the company to offer a complete range of short-term, long-term and permanent contraceptive methods for women.

April 5, 2013

The American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the Society of Adolescent Health and Medicine Friday morning commended a U.S. District Court ruling that expands over-the-counter access of Plan B One-Step to women under the age of 17.

WASHINGTON — The American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the Society of Adolescent Health and Medicine Friday morning commended a U.S. District Court ruling that expands over-the-counter access of Plan B One-Step to women under the age of 17. "This decision reflects the overwhelming evidence that emergency contraception is safe and effective for all women of reproductive age," the medical associations stated as part of a joint statement. 

February 14, 2013

Between 2006 and 2010, 1-in-9 sexually experienced women between the ages of 15 and 44 years had used emergency contraception at least once, the National Center for Health Statistics noted in a report released Wednesday.

ATLANTA — Between 2006 and 2010, 1-in-9 sexually experienced women between the ages of 15 and 44 years had used emergency contraception at least once, the National Center for Health Statistics noted in a report released Wednesday. Use of emergency contraception, such as Plan B One-Step, was the most common among women between the ages of 20 and 24 years, those who never married, Hispanic or non-Hispanic white women, and those who attended college. 

That compares with 2-in-5 women who used emergency contraception in 2002 and fewer than 1-in-10 women in 1995. 

December 27, 2012

Women deficient in vitamin D early in their pregnancies are more likely to deliver babies with lower birth weights, according to research released last week by the University of Pittsburgh Graduate School of Public Health.

PITTSBURGH — Women deficient in vitamin D early in their pregnancies are more likely to deliver babies with lower birth weights, according to research released last week by the University of Pittsburgh Graduate School of Public Health.

The study, funded by the National Institutes of Health, will be reported in the January print edition of the Journal of Clinical Endocrinology & Metabolism.

August 13, 2012

The Food and Drug Administration is reviewing a regulatory application from Teva for a contraceptive drug, the company said Monday.

FRAZER, Pa. — The Food and Drug Administration is reviewing a regulatory application from Teva for a contraceptive drug, the company said Monday.

Teva Women's Health, part of Israeli drug maker Teva Pharmaceutical Industries, announced the FDA's acceptance of its application for Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol), which the company called the first ascending-dose, extended regimen oral contraceptive for preventing pregnancy.

July 30, 2012

A number of smaller manufacturers of male contraceptives are launching into the market to challenge the big three: Church & Dwight (72.8% dollar share in the category), Ansell Healthcare (11.6% dollar share) and Reckitt Benckiser (11.5% dollar share).


A number of smaller manufacturers of male contraceptives are launching into the market to challenge the big three: Church & Dwight (72.8% dollar share in the category), Ansell Healthcare (11.6% dollar share) and Reckitt Benckiser (11.5% dollar share).


It’s one factor expected to drive more marketing around the category. Sales of condoms for the 52 weeks ended June 10 reached $295.5 million, up 5.1%, across food, drug and mass (excluding Walmart), according to SymphonyIRI Group.


July 13, 2012

The Food and Drug Administration has approved a generic contraceptive made by Watson Pharmaceuticals, the drug maker said Friday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic contraceptive made by Watson Pharmaceuticals, the drug maker said Friday.

Watson announced the approval of Next Choice One Dose (levonorgestrel) tablets in the 1.5-mg strength. The drug is an emergency contraceptive used to prevent pregnancy following unprotected sex or contraceptive failure.

The drug is a generic version of Teva Women's Health's Plan B One-Step, which had sales of about $88 million during the 12-month period ended in March, according to IMS Health.

April 3, 2012

A drug maker and a charity organization are donating $3 million in contraceptives to uninsured women.

SANTA BARBARA, Calif. — A drug maker and a charity organization are donating $3 million in contraceptives to uninsured women.

Teva Pharmaceuticals and Direct Relief USA announced the donation of 5,000 units of the intrauterine contraceptive ParaGard to clinics and health centers serving low-income people, including the EXCELth Family Health Center in New Orleans.

March 27, 2012

Pharmacies may be misinforming teenagers about where they can locate emergency contraceptives without a prescription, according to a new study published in Pediatrics.

NEW YORK — Pharmacies may be misinforming teenagers about where they can locate emergency contraceptives without a prescription, according to a new study published in Pediatrics.

March 15, 2012

The Food and Drug Administration has approved a drug that the manufacturer called the first oral contraceptive that also treats heavy menstrual bleeding.

WAYNE, N.J. — The Food and Drug Administration has approved a drug that the manufacturer called the first oral contraceptive that also treats heavy menstrual bleeding.

Bayer HealthCare Pharmaceuticals announced Wednesday the approval of Natazia (estradiol valerate and estradiol valerate and dienogest) tablets for heavy menstrual bleeding not caused by any conditions of the uterus. The drug was originally approved as an oral contraceptive in May 2010.

February 10, 2012

Controversy over a plan by the Obama administration to require health insurance plans to provide free contraception to women has led the administration to seek a policy that it is calling a compromise with conservative groups opposed to the measure, according to published reports.

NEW YORK — Controversy over a plan by the Obama administration to require health insurance plans to provide free contraception to women has led the administration to seek a policy that it is calling a compromise with conservative groups opposed to the measure, according to published reports.

The controversy surrounded the new rule's requirement that employee health insurance plans provide free birth control, including those run by the Roman Catholic church, such as hospitals and universities. The Church opposes birth control.

February 9, 2012

The Center for Reproductive Rights on Wednesday asked a federal court to reopen its 2005 lawsuit against the Food and Drug Administration for imposing age restrictions on emergency contraceptive drugs.

NEW YORK — The Center for Reproductive Rights on Wednesday asked a federal court to reopen its 2005 lawsuit against the Food and Drug Administration for imposing age restrictions on emergency contraceptive drugs. Presently, emergency contraceptives, like Plan B One Step, are available behind a pharmacy counter for women 17 years and older but require a prescription for women under the age of 17 years.

February 8, 2012

Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.

PARSIPPANY, N.J. — Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.

February 1, 2012

A possible pill mix-up has prompted Pfizer to recall more than two dozen lots of a prescription contraceptive drug, the drug maker said.

NEW YORK — A possible pill mix-up has prompted Pfizer to recall more than two dozen lots of a prescription contraceptive drug, the drug maker said.

Pfizer announced the voluntary nationwide recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 additional lots of the drug's generic version. Pfizer manufactured and packaged the drugs, while Akrimax Pharmaceuticals commercialized them, and they were sold under the Akrimax brand.

December 8, 2011

A group of medical associations on Wednesday denounced the government's decision to maintain the status quo with regard to the prescription status of the emergency contraceptive Plan B.

WASHINGTON — A group of medical associations on Wednesday denounced the government's decision to maintain the status quo with regard to the prescription status of the emergency contraceptive Plan B.

December 7, 2011

Food and Drug Administration commissioner Margaret Hamburg on Wednesday issued a public statement that the agency was prepared to approve Plan B as a nonprescription medication, but reversed that decision following a directive from the Department of Health and Human Services Wednesday morning.

SILVER SPRING, Md. — Food and Drug Administration commissioner Margaret Hamburg on Wednesday issued a public statement that the agency was prepared to approve Plan B as a nonprescription medication, but reversed that decision following a directive from the Department of Health and Human Services Wednesday morning.

October 13, 2011

The Centers for Disease Control and Prevention on Tuesday reported that the use of condoms is up in teen males.

ATLANTA — The Centers for Disease Control and Prevention on Tuesday reported that the use of condoms is up in teen males.

October 11, 2011

Indian generic drug maker Lupin has launched an authorized generic version of a birth control pill made by Warner Chilcott, according to published reports.

NEW YORK — Indian generic drug maker Lupin has launched an authorized generic version of a birth control pill made by Warner Chilcott, according to published reports.

Dow Jones reported that Lupin launched an authorized generic of Femcon (norethindrone and ethinyl estradiol tablets, ferrous fumarate tablets).

An authorized generic is a branded drug sold under its generic name at a reduced price, usually through a third-party company.

 

September 27, 2011

Watson Pharmaceuticals has launched a generic version of a contraceptive made by Warner Chilcott, Watson said Monday.

PARSIPPANY, N.J. — Watson Pharmaceuticals has launched a generic version of a contraceptive made by Warner Chilcott, Watson said Monday.

The drug maker announced the launch of chewable norethindrone and ethinyl estradiol tablets in the 0.4-mg/0.035-mg strength and chewable ferrous fumarate tablets in the 75-mg strength.

The product is a generic version of Warner Chilcott's Femcon Fe, which had sales of about $35 million during the 12-month period ended in July, according to IMS Health.

September 16, 2011

Qualitest Pharmaceuticals, an Endo Pharmaceuticals subsidiary, issued a voluntary, nationwide recall of multiple lots of oral contraceptives at the retail level.

HUNTSVILLE, Ala. — Qualitest Pharmaceuticals, an Endo Pharmaceuticals subsidiary, issued a voluntary, nationwide recall of multiple lots of oral contraceptives at the retail level.

Qualitest said it recalled lots of the following birth control pills due to a packaging error, whereby select blisters were rotated 180 degrees within the card, reversing the weekly tablet orientation and making the lot number and expiry date no longer visible. This error, the drug maker said, could leave women without adequate contraception and at risk for unintended pregnancy:

August 2, 2011

The Food and Drug Administration on Friday warned U.S. consumers not to use the emergency birth control medicine labeled as Evital, as it may be a counterfeit version of the “morning after pill” and may not be safe or effective in preventing pregnancy.

SILVER SPRING, Md. — The Food and Drug Administration on Friday warned U.S. consumers not to use the emergency birth control medicine labeled as Evital, as it may be a counterfeit version of the “morning after pill” and may not be safe or effective in preventing pregnancy.
 
In addition, no brand labeled Evital has been approved by the FDA for use in the United States.